drugset / Trial / NCT01905124
Safety &Efficacy of CF101 to Subjects With Uveitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.
Timeline
- Start
- 2019-01
- Primary completion
- 2019-09
- Completion
- 2019-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Piclidenoson | Small molecule | 1 mg | Oral |